Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer

BackgroundThere are no established predictive biomarkers for the effectiveness of first-line atezolizumab plus carboplatin and etoposide therapy in patients with small-cell lung cancer (SCLC). Therefore, the current study aimed to investigate whether the Glasgow prognostic score (GPS), neutrophil-to...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Satoshi Wasamoto, Hisao Imai, Takeshi Tsuda, Yoshiaki Nagai, Hiroyuki Minemura, Yutaka Yamada, Yukihiro Umeda, Takayuki Kishikawa, Ayako Shiono, Yuki Kozu, Jun Shiihara, Ou Yamaguchi, Atsuto Mouri, Kyoichi Kaira, Kenya Kanazawa, Hirokazu Taniguchi, Takayuki Kaburagi, Koichi Minato, Hiroshi Kagamu
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2023-01-01
Saila:	Frontiers in Oncology
Gaiak:	atezolizumab plus carboplatin and etoposide body mass index Glasgow prognostic score immune checkpoint inhibitor neutrophil-to-lymphocyte ratio small cell lung cancer
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1080729/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!